- Home
- TOL vs RPRX Comparison
TOL vs RPRX Comparison
Compare TOL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOL
- RPRX
- Stock Information
- Founded
- TOL 1967
- RPRX 1996
- Country
- TOL United States
- RPRX United States
- Employees
- TOL N/A
- RPRX N/A
- Industry
- TOL Homebuilding
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- TOL Consumer Discretionary
- RPRX Health Care
- Exchange
- TOL Nasdaq
- RPRX Nasdaq
- Market Cap
- TOL 11.9B
- RPRX 13.9B
- IPO Year
- TOL N/A
- RPRX 2020
- Fundamental
- Price
- TOL $121.98
- RPRX $37.11
- Analyst Decision
- TOL Buy
- RPRX Strong Buy
- Analyst Count
- TOL 15
- RPRX 4
- Target Price
- TOL $141.20
- RPRX $46.75
- AVG Volume (30 Days)
- TOL 1.6M
- RPRX 2.7M
- Earning Date
- TOL 08-19-2025
- RPRX 08-06-2025
- Dividend Yield
- TOL 0.82%
- RPRX 2.37%
- EPS Growth
- TOL N/A
- RPRX 37.60
- EPS
- TOL 13.50
- RPRX 2.45
- Revenue
- TOL $10,659,614,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- TOL $1.23
- RPRX $28.60
- Revenue Next Year
- TOL N/A
- RPRX $8.07
- P/E Ratio
- TOL $9.03
- RPRX $15.14
- Revenue Growth
- TOL 1.59
- RPRX 1.13
- 52 Week Low
- TOL $86.67
- RPRX $24.05
- 52 Week High
- TOL $169.52
- RPRX $37.57
- Technical
- Relative Strength Index (RSI)
- TOL 56.22
- RPRX 62.93
- Support Level
- TOL $117.50
- RPRX $35.24
- Resistance Level
- TOL $124.39
- RPRX $37.55
- Average True Range (ATR)
- TOL 3.61
- RPRX 0.65
- MACD
- TOL -0.47
- RPRX 0.04
- Stochastic Oscillator
- TOL 54.44
- RPRX 80.43
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. It has its headquarters in Horsham, Pennsylvania.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.